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 25 
Abstract 26 
Rationale: Giant-cell arteritis (GCA) is a large vessel vasculitis characterized by 27 
immune cell infiltration, yet the potential involvement of neutrophils has been rarely 28 
studied.  29 
Objective: We investigated whether alterations in neutrophil reactivity occurred in 30 
the pathogenesis of GCA, or during its clinical management with a canonical 31 
glucocorticoid dose regimen over a 6-month period. 32 
Methods and Results: Blood samples were taken within 48h of therapy       33 
commencement and at week-1, 4 and 24 post-glucocorticoid. Flow-cytometric 34 
analysis revealed three distinct neutrophils populations and phenotypes. Within 35 
48hrs of steroid treatment, neutrophils displayed an AnxA1hiCD62LloCD11bhi 36 
phenotype, whereas week-1 neutrophils were AnxA1hiCD62LloCD11blo and displayed 37 
minimal adhesion to endothelial monolayers under flow, and week 24 (i.e. lowest 38 
glucocorticoid dose) neutrophils were AnxA1hiCD62LhiCD11bhi with increased 39 
endothelial adhesion under flow. Week 24 plasma analyses showed high levels of 40 
CXCL5, IL-8, IL-17 and IL-6. Importantly, comparison of week-1 and 24 samples 41 
revealed a suppressive neutrophil effect on T-cell proliferation at the former time 42 
point only. Finally, in vitro incubation of naïve neutrophils with concentrations of IL-6 43 
and IL-17 quantified in GCA plasma at week-1 and 24 replicated this differential 44 
modulation of lymphocyte proliferation.  45 
Conclusion: This translational study highlights a novel clinical manifestations of 46 
GCA, with evidence for a neutrophil component and an ‘escaped’ pro-inflammatory 47 
phenotype when glucocorticoid therapy is tapered. These results indicate potential 48 
involvement of neutrophils in GCA pathogenesis. 49 
 50 
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Abbreviations: GCA giant cell arteritis,; OA, osteroarthritis,  52 
Introduction 53 
Giant-cell arteritis (GCA) is a systemic inflammatory disease associated with focal 54 
granulomatous panarteritis predominantly involving extracranial branches of the 55 
aorta. The most feared complication is critical ischemia leading to anterior ischemic 56 
optic neuropathy and permanent sight loss (~20% of cases). Clinical management of 57 
GCA is with immediate high-dose glucocorticoids started on suspicion, with tapering 58 
over several months1 depending on the patients’ clinical response to treatment.  59 
 60 
GCA is considered a Th1 and Th17 T-cell mediated disease. IFN-gamma secreting 61 
Th1 cells are relatively glucocorticoid-resistant and largely responsible for chronic 62 
disease activity. In contrast, raised plasma IL-17 levels and Th17 cell arterial wall 63 
infiltration is steroid sensitive2. It is noteworthy that a pivotal property of IL-17 64 
(referred to herein as IL-17) is neutrophil activation, yet studies on neutrophil 65 
phenotype in GCA pathology are scant3, 4. 66 
 67 
Materials and Methods 68 
(Extended details in Supplemental Materials). 69 
Patients  70 
This study is conducted in accordance with the Declaration of Helsinki. Patients gave 71 
informed consent and samples were collected from Southend University and 72 
Hammersmith Hospitals (protocol approved by the East London & The City Local 73 
Research Ethics Committee; Table 1 for patient demographics). 74 
 75 
Flow-cytometry 76 
A whole blood staining protocol was performed as described5. 77 
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 78 
Flow chamber assay 79 
Human umbilical vein endothelial cells (HUVEC) (ethics as above) were stimulated 80 
with TNF-α (10 ng/mL, 4h). Blood neutrophils were isolated via density gradient6 and 81 
analysis of total cell capture, rolling and firmly adherent neutrophils was performed 82 
off-line6. 83 
 84 
Determination of plasma cytokine levels 85 
Plasma prepared from blood of patients was tested for CXCL5, IL-8, IL-6, sIL-6R, IL-86 
17 and IFN-gamma by ELISA. 87 
 88 
Statistical analyses 89 
Either paired Student’s T test (for 48 h and week-1 post-steroid samples) or one-way 90 
repeated measures ANOVA for longitudinal analyses were carried out. Statistical 91 
differences were accepted if P<0.05. 92 
 93 
Results  94 
Longitudinal changes in GCA neutrophil phenotype and circulating numbers  95 
Neutrophilia was observed within 48h of prednisone commencement (~5x106 96 
neutrophils/ml) and at 1 and 24-weeks post-steroid (~4x106/ml; Table 1) when 97 
compared to both patient control groups (~1.2x106/ml; P<0.05).  Longitudinal 98 
expression of the glucocorticoid-regulated protein Annexin A1 (AnxA1) revealed high 99 
neutrophil surface expression as early as 48h post-therapy and at week-1, 100 
approximately 3-4-fold increase above OA and high-dose steroid controls (Figure 101 
1A); this peak declined steadily by week-4. However, an increase was detected 102 
again at week 24 corresponding to glucocorticoid tapering (Figure 1A). This is a non-103 
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genomic response, since no significant difference in AnxA1 mRNA was observed 104 
across the groups (Online Figure II). Expression of the AnxA1 receptor ALX/FPR2 105 
did not change at any time point (Figure 1B). 106 
 107 
We next analyzed the longitudinal expression of CD62L and CD11b. GCA 108 
neutrophils expressed low levels of CD62L when compared to the two control 109 
groups, with reduction evident as early as 48h post-therapy commencement. Values 110 
began to increase from week-4, with higher cellular expression by week 24 (Figure 111 
1A,B; P<0.05). Although CD11b expression was high at 48h, it rapidly decreased by 112 
week-1 (Figure 1A) with no significant difference from controls. Again there was a 3-113 
fold selective increase in CD11b on GCA neutrophils at week 24 (Figure 1A). 114 
 115 
Therefore, within 48hrs of steroid treatment, neutrophils displayed an 116 
AnxA1hiCD62LloCD11bhi phenotype, week-1 CD16+ neutrophils displayed an 117 
AnxA1hiCD62LloCD11blo phenotype, and week-24 Online Figure III). These 118 
phenotypes correlated with neutrophil-endothelial cell interactions under flow. There 119 
was a 3-fold decrease in GCA-neutrophil interactions at week-1 (as compared to 120 
OA), due to marked attenuation in rolling and adhesion (Figure 1C).  In contrast, 121 
week-24 GCA neutrophils exhibited significantly increased capture and adhesion 122 
(Figure 1C). 123 
 124 
Suppressor neutrophil reduction at 24-weeks post-glucocorticoid 125 
Plasma analyses of the chemokines IL-8 and CXCL5 indicated a significant increase 126 
within 48hrs of steroid commencement, declining at 1 and 4 weeks post-steroid. 127 
However, there was a significant augmentation of both neutrophil chemoattractants 128 
at 24 weeks post steroid, with levels similar to that observed at 48hrs (Figure 2A). 129 
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Plasma IFN-γ levels were signiificantly high 48hrs post therapy, compared to 130 
controls groups and 1 week post steroid, but there was no further significant changes 131 
in IFN-γ levels was observed during the rest of the time course (Figure 2A). In 132 
contrast to IFN- γ, IL-6 levels increased in GCA patients 24-weeks post-steroid, 133 
which coincided with an increase in IL-17 (Figure 2A). 134 
 135 
A recent study described a novel CD16brightCD62Ldim population of neutrophils that 136 
suppress T-cell proliferation7. Re-analysis of our data revealed a significant reduction 137 
of CD16hiCD62Llo events (equivalent to CD16bightCD62Ldim suppressors) at week 24 138 
when compared to week-1 (Figure 2B), with higher levels of AnxA1 compared to 139 
week-1 (Figure 2B). Incubation of neutrophils from healthy donors with 140 
concentrations of IL-17 and IL-6 measured in GCA patient plasma at week-1 and 24 141 
replicated the difference in the neutrophil suppressor population (Figure 3A) and 142 
their ability to suppress T cell proliferation: neutrophils treated with week-1 levels of 143 
the two cytokines were able to effectively suppress T cell proliferation, but not when 144 
treated with week-24 levels of IL-6 and IL-17 (Figure 3B).  145 
 146 
Finally, we quantified chemokine receptor expression on T-cells following co-culture 147 
with neutrophils treated with IL-6 and IL-17 in combination. Whereas CXCR4 148 
expression did not significantly change (data not shown), a 2-3-fold increase in T-cell 149 
CXCR3 expression was observed upon co-culture with week 24, but not week-1 150 
concentrations of IL-6 and IL-17 (Figure 3C).151 
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Discussion 152 
The recent identification of IL-17-producing T-cells in GCA patients2 suggests a 153 
potential role for neutrophils, since this cytokine promotes bone marrow mobilization 154 
as well as activation and trafficking of neutrophils into perivascular tissue8 , yet there 155 
is scant evidence for a role for neutrophils in GCA3, 4. We monitored neutrophil 156 
function and phenotypes during a canonical 6-month glucocorticoid treatment, and 157 
provide evidence for a role for neutrophil phenotypic changes in GCA pathology.  158 
 159 
Our initial interest in neutrophils and GCA stemmed from the neutrophilia typically 160 
seen in patients on steroid therapy (Table 1). Persistent neutrophilia observed at 24-161 
weeks (a time when most patients have achieved clinical remission), suggested 162 
existence of a sub-clinical vascular inflammatory state that might explain disease 163 
reemergence. To test this hypothesis, we analyzed neutrophil phenotypes as early 164 
as 48h post-steroid and at 1, 4 and 24-weeks post-therapy. GCA neutrophils display 165 
a classically activated CD16hiAnxA1hiCD62LloCD11bhi phenotype at 48 h. This 166 
phenotype comes under rapid control within1-week of treatment, in spite of stable 167 
neutrophilia, with a CD16hiAnxA1hiCD62LloCD11blo signature. These neutrophils 168 
were hyporeactive as confirmed by minimal interaction with an inflamed endothelial 169 
monolayer under flow conditions, similar to the CD16brightCD62Ldim neutrophil 170 
reactivity previously described9. This neutrophil phenotype is similar to that reported 171 
following oestrogen treatment5.  In stark contrast, neutrophils at 24-weeks post-172 
glucocorticoids exhibited a CD16hiAnxA1hiCD62LhiCD11bhi  phenotype correlating 173 
with marked adhesion to endothelial monolayers. 174 
 175 
We initially postulated the neutrophil phenotype observed at week-1 was a direct 176 
consequence of high-dose steroid therapy, since AnxA1 is glucocorticoid 177 
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regulated10, and there is evidence for glucocorticoid-induced CD62L shedding11. 178 
However this protective neutrophil phenotype was specific to steroid-treated GCA, 179 
since cells from the high-dose steroid control group did not display the same 180 
hyporeactive phenotype. Furthermore, despite the high AnxA1 levels on week 24 181 
neutrophils, there was still significantly increased firm adhesion, suggesting either a 182 
defective protein5, 6 or inability to counteract the cellular hyperactivity. The molecular 183 
mechanisms behind AnxA1 mobilization at week-1 and 24 warrant further 184 
investigation.  185 
 186 
The emerging hypothesis of a neutrophil component in GCA was confirmed by 187 
cytokine measurements: the highest circulating levels of CXCL5 and IL-8, together 188 
with IL-6 and IL-17, were observed at week 24 (Figure 2).  It should also be noted 189 
that levels of both neutrophil chemoattractants and IFN-γ were significantly 190 
augmented within 48hrs of steroid commencement, when compared to high dose 191 
steroid controls who had been on steroid therapy for a similar length of time. 192 
Therefore, taken together, this neutrophil component appears to be specific to GCA. 193 
Increased IL-17 expression following therapeutic control is congruent with a model 194 
whereby T-cell/neutrophil crosstalk is key to GCA progression, possibly exacerbating 195 
vascular inflammation.  196 
 197 
Near completion of this study, two neutrophil phenotypes were reported in the blood 198 
of volunteers infused with lipopolysaccharide, with a novel suppressor pool, identified 199 
as CD16brightCD62LdimCD11bbright, able to dampen T-cell activation7. This suppressor 200 
pool was detected in our week-1 samples, and almost halved by at week 24 post-201 
steroid, making the present GCA study the first to identify this neutrophil subset in 202 
disease. Combining our functional data with those of Pillay et al7, we hypothesize 203 
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that week-24 GCA neutrophils are unable to suppress T-cell responses, favoring loss 204 
of glucocorticoid control and, in time, re-emergence of vascular inflammation.  205 
 206 
Intriguingly, we could reproduce in vitro the neutrophil dichotomy using 207 
concentrations of IL-6 and IL-17 equivalent to those measured in GCA plasma 208 
samples. The reduction in suppressor neutrophils, after treatment with these 209 
cytokines correlated with attenuated inhibition of lymphocyte proliferation. 210 
Furthermore, analysis of T-cells co-cultured with these neutrophils demonstrated 211 
high levels of the chemokine receptor CXCR3, an important determinant for Th1 and 212 
Th17 cell trafficking to inflamed tissues12, 13. Indeed, CXCR3+ T-cells have been 213 
identified in the temporal arteries of GCA patients14.  214 
 215 
In conclusion, we report potential involvement of neutrophils in GCA pathogenesis 216 
and/or relapse. Our data support the concept that the disease process is 217 
incompletely controlled by glucocorticoid therapy, since tapering leads to loss of the 218 
neutrophil suppressor subset. This, in turn, may be the prelude to lymphocyte 219 
proliferation and disease relapse with an associated increased risk of vascular 220 
complications (Figure 4). Thus, monitoring neutrophil phenotype might inform on 221 
disease status, predict risk of relapse and facilitate steroid tapering in individual 222 
patient. 223 
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Table 1. Patient demographics 233 
Ratio (F:M) 
Age 
(Yrs) 
Time post 
Steroid 
Neutrophil 
count CRP 
(mg/L) 
Steroid dose 
(mg/day) (X106/ml 
blood) 
GCA Patients     
5:0  48hr (n=5) 5.9±1.1 43.0±10.5 63.3±3.3 
11:3 72±2.0 1 week (n=14) 4.4±0.9*# 72.8±23.0 57.8±2.2 
6:3  4 weeks (n=9) 2.6±0.4 1.61±0.4 40.0±2.8 
6:3  24 weeks (n=9) 4.3±0.6*# 11.9±4.8 13.4±2.2 
OA controls      
8:2 70±3.3 N/A 1.3±0.2 2.8±0.9 N/A 
High dose steroid controls    
5:1 47±9.8 ≤ 1 week 2.2±0.3 18.5±5.6 48.0±3.7 
 234 
Reported here are the patient demographics for GCA and two control groups: age-235 
matched osteoarthritis (OA) patients and high dose steroid controls (heterogeneous: 236 
Takayasu’s arteritis, n=3, and ANCA vascultis patients, n=3). Data are expressed as 237 
mean±SEM (n). *P<0.05 compared to OA controls; #P<0.05 compared to high dose 238 
steroids (One-way ANOVA). No statistical difference emerged between the age 239 
range of GCA and OA patients. 240 
 241 
 242 
 243 
 244 
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 246 
Figure Legends 247 
Figure 1. Longitudinal neutrophil phenotyptic and reactivity changes in GCA. 248 
A. Analysis of neutrophil phenotype with respect to AnxA1, FPR2/ALX, CD62L and 249 
CD11b in GCA blood 48hrs post steroid (n=5) and at 1, 4 and 24 weeks post steroid 250 
(n=9; open circles), compared to OA (n=10; white bars) and high dose steroid (n=6; 251 
hatched bars) controls. B. GCA neutrophils at 1 and 24-weeks post-steroid were 252 
flowed over activated HUVEC monolayers under shear. GCA neutrophil reactivity 253 
was compared with OA neutrophils. Representative images are shown. P<0.05 ‡ 254 
compared to 48hr,♯compared to OA, §compared to high-dose steroid, *compared to 255 
GCA week-1. 256 
Figure 2. Suppressor neutrophil population in GCA.   257 
A. Plasma samples collected from GCA 48hrs post steroid (n=5) and at 1, 4 and 24 258 
weeks post steroid (n=9; open circles) were analyzed for IL-6,IL-17, CXCL5, IL-8, 259 
IFNγ and sIL-6R  and compared to OA (n=10; white bars) or high dose steroid 260 
controls (n=6, hatched bars).  B. Neutrophils from GCA patients gated as 261 
CD16hiCD62Lhi  (white bars) or CD16hiCD62Llo (hatched bars) populations (left panel) 262 
were further analyzed for AnxA1 (middle panel) and CD11b (right panel) expression. 263 
Representative plots of CD16 and CD62L distribution on neutrophils are shown. 264 
P<0.05, *compared to week 1, #compared to OA control, §compared to high dose 265 
steroids, +compared to 48hr. 266 
Figure 3. In vitro GCA suppressor neutrophils. 267 
 A. Neutrophils from healthy donors were treated in vitro with vehicle (white bars), 268 
week-1 (light grey bars) or week 24 (dark grey bars) concentrations of IL-6 and IL-17 269 
measured in GCA plasma (see Figure 2). Representative plots are shown. B. 270 
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Proliferation assay. Neutrophils were washed and co-cultured with autologous 271 
CFSE-labelled T-cells stimulated with anti-CD3 and anti-CD28. Proliferation was 272 
analysed 5 days post co-culture. C. CXCR3 expression on T-cells following in vitro 273 
co-culture.  Data are from three separate experiments, P<0.05; *compared to week-274 
1; §compared to vehicle.  275 
 276 
 277 
Figure 4. Potential role for neutrophils in GCA disease progression 278 
Hypothetical role(s) of neutrophils in GCA (see Discussion). Blue neutrophil depicts 279 
neutrophil at 1 week post-steroid, which is capable of tempering T cell responses 280 
and limiting inflammation. Red neutrophil depicts neutrophil at week 24 post-steroid, 281 
where we hypothesis this cell is now unable to control T cell responses, hence 282 
leaving unchecked T cell migration to the affected vessel possibly via CXCR3 283 
upregulation. 284 
285 
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What is known? 337 
• Giant Cell Arteritis (GCA) is a large vessel vasculatides characterized by 338 
inflammation of the temporal artery, burdened by a risk of blindness. 339 
• On suspicion of GCA, large dose therapy with glucocorticoids is immediately 340 
commenced, which is tapered over 6 months, provided the patient is showing 341 
clinical signs of improvement. 342 
• Mechanistically, T cell recruitment and activation into the temporal artery is 343 
considered responsible for pathogenesis. 344 
 345 
What New Information Does this Article Contributes? 346 
• Analyses of circulating neutrophils revealed cell activation during the early 347 
stage of the disease which then became controlled by large dose 348 
glucocorticoids. 349 
• Indication for two neutrophil phenotypes could be found, including one able to 350 
suppress T cell proliferation. 351 
• At the end of the 6-month glucocorticoid regimen, this ‘suppressor phenotype’ 352 
is less expressed, and there is re-emergence of signs of neutrophil activation 353 
coupled to higher levels of pro-inflammatory cytokines. 354 
 355 
An involvement of T cells in the pathogenesis of GCA is accepted, however, 356 
mechanisms regulating their hyper-reactivity are poorly understood. We examined, 357 
longitudinally over a 6-month glucocorticoid regimen period, the profile of circulating 358 
leukocytes, observing selective modulation of neutrophil phenotype and reactivity. 359 
When high dose steroids were given, a non-inflamed phenotype of the circulating 360 
neutrophil was determined with a larger proportion of the suppressor type, since 361 
these neutrophils inhibited T cell proliferation. However, when steroids were tapered, 362 
there were clear signs of neutrophil activation associated with high levels of two pro-363 
inflammatory cytokines, interleukin-6 and interleukin-17A. This was associated with a 364 
reduction of the proportion of the neutrophils with the suppressor phenotype. 365 
Collectively, these results suggest a potential involvement of neutrophils in the 366 
pathogenesis of GCA and might indicate novel interactions between neutrophils and 367 
T cells. High doses of glucocorticoids establish an effective control on these 368 
interactions, however when doses are tapered, there may be still subliminal signs of 369 
vascular inflammation possibly conducive to subsequent disease relapse and 370 
associated risk of vascular complications. Monitoring neutrophil phenotype can 371 
provide novel information on disease status, risk of relapse and steroid dosage. 372 
 373 
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